295 related articles for article (PubMed ID: 3658288)
41. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
[TBL] [Abstract][Full Text] [Related]
42. [Combined chemo- and hormone-therapy in advanced ovarian carcinoma--theoretical, experimental foundations and clinical results].
Sevelda P
Wien Klin Wochenschr Suppl; 1990; 183():3-29. PubMed ID: 2145702
[TBL] [Abstract][Full Text] [Related]
43. High-dose-intensity regimen of weekly doxorubicin and cisplatin in the treatment of patients with stage III and IV epithelial ovarian carcinoma.
O'Connell G; Shelley W; Carmichael J; Fraser R; Kirk ME; Krepart G; Levin L; Swenerton K
Cancer Treat Rep; 1987 May; 71(5):455-8. PubMed ID: 3567969
[TBL] [Abstract][Full Text] [Related]
44. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
[TBL] [Abstract][Full Text] [Related]
45. [Combination chemotherapy of urothelial cancer with cisplatin, cyclophosphamide, doxorubicin and peplomycin: treatment of advanced cases and adjuvant chemotherapy after radical operation].
Seguchi T; Sakaguchi H; Kajikawa H; Nishioka T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):600-5. PubMed ID: 2435245
[TBL] [Abstract][Full Text] [Related]
46. Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy.
Bruckner HW; Ratner LH; Cohen CJ; Wallach R; Kabakow B; Greenspan EM; Holland JF
Cancer Treat Rep; 1978 Jul; 62(7):1021-3. PubMed ID: 688244
[TBL] [Abstract][Full Text] [Related]
47. [Studies of second-look operations (SLO) in ovarian cancer].
Yuzawa H
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822
[TBL] [Abstract][Full Text] [Related]
48. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
Kobayashi H; Hayata T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
[TBL] [Abstract][Full Text] [Related]
49. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE
Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056
[TBL] [Abstract][Full Text] [Related]
50. [Evaluation of the efficacy of cisplatin-based chemotherapy in epithelial ovarian cancer; comparison with treatments employed before the cisplatin era].
Kamura T; Tsukamoto N; Suenaga T; Kaku T; Matsukuma K; Matsuyama T
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1260-3. PubMed ID: 3579324
[TBL] [Abstract][Full Text] [Related]
51. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.
Edmonson JH; McCormack GW; Krook JE; Long HJ; Jefferies JA; Richardson RL
Cancer Treat Rep; 1987 Feb; 71(2):199-200. PubMed ID: 3542210
[TBL] [Abstract][Full Text] [Related]
52. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
53. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
54. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
55. [Reassessment of second-look operations (SLO) in the treatment of ovarian cancer].
Ochiai K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1303-9. PubMed ID: 2730043
[TBL] [Abstract][Full Text] [Related]
56. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
Vogl SE; Berenzweig M; Kaplan BH; Moukhtar M; Bulkin W
Cancer Treat Rep; 1979 Feb; 63(2):311-7. PubMed ID: 109202
[TBL] [Abstract][Full Text] [Related]
57. Toxicity of abdominopelvic radiation in advanced ovarian carcinoma patients after cisplatin/cyclophosphamide therapy and second-look laparotomy.
Shelley WE; Starreveld AA; Carmichael JA; O'Connell G; Roy M; Swenerton K
Obstet Gynecol; 1988 Mar; 71(3 Pt 1):327-32. PubMed ID: 3347416
[TBL] [Abstract][Full Text] [Related]
58. [Expectations and defeat in the treatment of epithelial cancer of the ovary].
Weil M; Borel C; Auclerc G; Forget G; Durandin-Truffinet M; Thill L; Khayat D; Jacquillat C
Ann Med Interne (Paris); 1990; 141(1):15-9. PubMed ID: 2321883
[TBL] [Abstract][Full Text] [Related]
59. Stage III-IV epithelial carcinoma of the ovary: is the second-look operation of any value for the patient?
Atad J; Bornstein J; Steiner M; Weill S; Lurie M; Abramovici H
Isr J Med Sci; 1988 Nov; 24(11):660-3. PubMed ID: 3215758
[TBL] [Abstract][Full Text] [Related]
60. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
